3 ASX All Ords shares leading the charge in 2025
These ASX All Ords shares have soared 16% to 37% already in 2025. The post 3 ASX All Ords shares leading the charge in 2025 ...
Where is the next Chinese drug that will make MNCs compete to grab orders?
The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantically.Recently ...
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 ...
Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation
Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...
FierceBiotech18h
Astellas calls it quits on early-stage lymphoma CAR-T following pipeline review
On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...
emjreviews.com20h
Breakthrough in Relapsed DLBCL Treatment
A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...
Scientific Research Publishing22h
Multiple Myeloma in Young African Woman with Systemic Lupus Erythematosus and Sjögren Syndrome: A Case Report ()
We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...